| 摘要 |
<P>PROBLEM TO BE SOLVED: To provide not only for vaccines against Staphylococcus aureus infection but also, in particular, for vaccines with enhanced antigen stability. <P>SOLUTION: A lyophilized immunogenic composition comprises: (a) at least three components selected from the group consisting of an isolated Staphylococcus aureus clumping factor A (ClfA) polypeptide, an isolated Staphylococcus aureus clumping factor B (ClfB) polypeptide, a capsular polysaccharide type 5 (CP5)-protein conjugate, a capsular polysaccharide type 8 (CP8)-protein conjugate, and an isolated Staphylococcus aureus MntC polypeptide; (b) a buffer having pKa of 6.0±0.6; and (c) a filler; wherein the ClfA polypeptide remains substantially undegraded for at least 1 month at 37°C. <P>COPYRIGHT: (C)2012,JPO&INPIT |
